Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Puja Sapra

Showing results (21-30 of 56) with videos related to

Pageof 6
Sort By:
Targeted Oncology|July 24, 2019
Combination Treatment with an Antibody-Drug Conjugate (A1mcMMAF) Targeting the Oncofetal Glycoprotein 5T4 and Carboplatin Improves Survival in a Xenograft Model of Ovarian CancerY Louise Wan, Puja Sapra, James Bolton, et al.
Targeted Oncology|October 5, 2019
Correction to: Combination Treatment with an Antibody-Drug Conjugate (A1mcMMAF) Targeting the Oncofetal Glycoprotein 5T4 and Carboplatin Improves Survival in a Xenograft Model of Ovarian CancerY Louise Wan, Puja Sapra, James Bolton, et al.
Cancer Research|January 9, 2003
Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude miceFabio Pastorino, Chiara Brignole, Danilo Marimpietri, et al.
Blood|August 20, 2005
Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxinChien-Hsing Chang, Puja Sapra, Sailaja S Vanama, et al.
Haematologica|March 26, 2017
Targeting the 5T4 oncofetal glycoprotein with an antibody drug conjugate (A1mcMMAF) improves survival in patient-derived xenograft models of acute lymphoblastic leukemiaOwen J McGinn, Shekhar Krishnan, Jean-Pierre Bourquin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2008
Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory modelPuja Sapra, Hong Zhao, Mary Mehlig, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2015
Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or TaxanesBoris Shor, Jennifer Kahler, Maureen Dougher, et al.
Annals of the New York Academy of Sciences|August 16, 2014
Antibody-drug conjugates: an emerging modality for the treatment of cancerMauricio Leal, Puja Sapra, Sara A Hurvitz, et al.
Journal of Pharmacokinetics and Pharmacodynamics|August 13, 2013
On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approachNahor Haddish-Berhane, Dhaval K Shah, Dangshe Ma, et al.
Molecular Cancer Therapeutics|November 1, 2008
A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growthLee M Greenberger, Ivan D Horak, David Filpula, et al.
Pageof 6

Showing results (21-30 of 56) with videos related to

Sort By:
Pageof 6
Targeted Oncology|July 24, 2019
Combination Treatment with an Antibody-Drug Conjugate (A1mcMMAF) Targeting the Oncofetal Glycoprotein 5T4 and Carboplatin Improves Survival in a Xenograft Model of Ovarian CancerY Louise Wan, Puja Sapra, James Bolton, et al.
Targeted Oncology|October 5, 2019
Correction to: Combination Treatment with an Antibody-Drug Conjugate (A1mcMMAF) Targeting the Oncofetal Glycoprotein 5T4 and Carboplatin Improves Survival in a Xenograft Model of Ovarian CancerY Louise Wan, Puja Sapra, James Bolton, et al.
Cancer Research|January 9, 2003
Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude miceFabio Pastorino, Chiara Brignole, Danilo Marimpietri, et al.
Blood|August 20, 2005
Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxinChien-Hsing Chang, Puja Sapra, Sailaja S Vanama, et al.
Haematologica|March 26, 2017
Targeting the 5T4 oncofetal glycoprotein with an antibody drug conjugate (A1mcMMAF) improves survival in patient-derived xenograft models of acute lymphoblastic leukemiaOwen J McGinn, Shekhar Krishnan, Jean-Pierre Bourquin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2008
Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory modelPuja Sapra, Hong Zhao, Mary Mehlig, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2015
Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or TaxanesBoris Shor, Jennifer Kahler, Maureen Dougher, et al.
Annals of the New York Academy of Sciences|August 16, 2014
Antibody-drug conjugates: an emerging modality for the treatment of cancerMauricio Leal, Puja Sapra, Sara A Hurvitz, et al.
Journal of Pharmacokinetics and Pharmacodynamics|August 13, 2013
On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approachNahor Haddish-Berhane, Dhaval K Shah, Dangshe Ma, et al.
Molecular Cancer Therapeutics|November 1, 2008
A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growthLee M Greenberger, Ivan D Horak, David Filpula, et al.
Pageof 6